The therapeutic logic of the study rests on the biology of bone morphogenetic proteins, or BMPs, which belong to the transforming growth factor beta superfamily. Although their name reflects their original discovery as inducers of bone and cartilage formation, BMPs are far more versatile than that label suggests. In the developing and mature central nervous system, they act as morphogens and survival factors, shaping neural fate decisions, guiding differentiation, and maintaining the functional integrity of neuronal circuits. The BMP2/6-SMAD1 signaling axis, in particular, has been shown to play a pivotal role in the development and functional maturation of nigrostriatal dopaminergic circuits, the very circuitry that degenerates in Parkinson’s disease. Because SMAD1 is the canonical intracellular mediator downstream of BMP receptors, activation of this pathway in dopaminergic neurons can trigger transcriptional programs that support cell survival, resilience against stress, and proper neuronal differentiation.

Translating that developmental biology into a therapy for an adult neurodegenerative disease, however, requires solving two problems at once. First, the protein must reach the target cells inside the brain. Second, it must do so in a way that is compatible with repeated, long-term administration in patients. Recombinant proteins are large, hydrophilic molecules that do not cross the blood-brain barrier in meaningful quantities, and invasive delivery into the brain parenchyma is impractical for a chronic disease. The research team addressed this by choosing the intranasal route, in which proteins administered into the nasal cavity can reach the central nervous system along olfactory and trigeminal nerve-associated pathways, bypassing the blood-brain barrier entirely. Intranasal delivery is non-invasive, can be self-administered, and has emerged in recent years as a practical gateway for biologics that would otherwise be excluded from the brain.

On the laboratory side, the investigators began with a cellular model designed to reproduce a key molecular insult of Parkinson’s disease. Neural stem cells were transduced with a lentiviral vector carrying A53T-mutant alpha-synuclein, a form of the protein linked to familial Parkinson’s disease and notorious for its propensity to misfold and aggregate. Overexpression of A53T alpha-synuclein in these cells creates a toxic intracellular environment that compromises viability, proliferation, and the capacity of the cells to differentiate along neuronal lineages. When the researchers treated these stressed neural stem cells with recombinant BMP2 and BMP6, they observed a clear rescue: the treated cells showed improved viability, better proliferation, and restored differentiation capacity. This set of results suggested that BMP2/6 signaling can counteract some of the damage inflicted by alpha-synuclein pathology and may exert protective effects on the survival and differentiation of dopaminergic neurons themselves.

Encouraged by the in vitro findings, the team moved into animal models that are standard for preclinical Parkinson’s research. They used two complementary lesion paradigms in mice. The first relied on 6-hydroxydopamine, a catecholaminergic neurotoxin that is taken up selectively by dopaminergic neurons and destroys them through oxidative stress, producing a rapid and reproducible loss of nigrostriatal neurons. The second used alpha-synuclein preformed fibrils, synthetic seeds of misfolded alpha-synuclein that, when introduced into the brain, recruit endogenous alpha-synuclein into pathological aggregates and trigger a slower, more disease-like progressive neurodegeneration accompanied by phosphorylated alpha-synuclein inclusions. Using both models matters because they probe different aspects of the disease: one tests whether neurons can be protected from acute chemical insult, while the other tests whether the treatment can interfere with the protein aggregation cascade that defines Parkinson’s pathology in patients.

In both lesioned mouse groups, the treatment consisted of mouse BMP2/6 recombinant proteins delivered intranasally. The results were consistent across the paradigms. Intranasal BMP2/6 significantly delayed the degeneration of dopaminergic neurons compared with control animals that received the same lesions without the protein therapy. Histological assessment of the substantia nigra and striatum showed that more dopaminergic neurons survived in the treated animals, and the preservation of neurons translated into functional benefit. On the rotarod test, a standard measure of motor coordination and balance in which mice must remain on a rotating rod for as long as possible, the BMP2/6-treated mice performed better than their untreated counterparts. The apomorphine-induced rotation test, which measures asymmetric turning behavior caused by dopamine imbalance between the two sides of the brain after apomorphine administration, likewise showed improvement in treated animals. Together, these behavioral assays demonstrated that the neuronal protection achieved at the cellular level was sufficient to preserve motor function, the clinical dimension that matters most to patients.

The mechanistic thread running through the study is the reactivation of SMAD1 signaling in a context where it has been weakened or overwhelmed by pathological stress. During normal development, BMP2 and BMP6 help dopaminergic neurons acquire their mature identity and maintain their circuitry, and the authors argue that this same pathway can be recruited therapeutically in the adult brain. By supplying recombinant ligands through the nose, the treatment effectively amplifies an endogenous survival signal at a time when alpha-synuclein toxicity, oxidative damage, and inflammatory stress are pushing neurons toward degeneration. The improved survival and differentiation of A53T alpha-synuclein-overexpressing neural stem cells in vitro further hints that BMP2/6 may support not only the survival of existing neurons but also the health of the neural stem cell compartment, a possibility with implications for endogenous repair mechanisms.

Several features of this work make it noteworthy in the crowded field of Parkinson’s neuroprotection. Most candidate neuroprotective agents tested in animal models have failed to translate into humans, often because of delivery problems, dosing limitations, or the fact that interventions began too late in the disease process. The intranasal approach sidesteps the blood-brain barrier without requiring surgery or implanted devices, and protein-based therapy avoids some of the off-target concerns associated with small molecules. Moreover, because BMP2/6 acts on a pathway intrinsic to dopaminergic neuron maintenance rather than on a single pathological species such as aggregated alpha-synuclein, it could in principle complement therapies aimed at aggregation, inflammation, or other disease mechanisms. The authors frame their findings as evidence for a potential role in early neuroprotection, which aligns with the growing consensus that disease-modifying treatment in Parkinson’s must begin before extensive neuronal loss has occurred.

Important caveats remain before this approach can be considered for clinical development. The study was conducted in mice, and rodent models of Parkinson’s disease, while informative, do not fully capture the complexity of the human illness, which involves multiple brain regions, non-motor symptoms, and decades of progression. The dose, frequency, and duration of intranasal protein delivery that would be required in humans are unknown, and the long-term safety of repeatedly activating BMP signaling in the adult brain will need careful evaluation, since BMP pathways participate in diverse processes beyond neuronal survival. It is also not yet established how much of the intranasally delivered protein reaches the human substantia nigra, a deep midbrain structure, although the olfactory route has been shown to deliver biologics to the central nervous system in other contexts. The published version of the study is open access and carries the DOI 10.1186/s12916-026-05269-x, allowing the scientific community to examine the full data, including the supplementary figures and original western blot images that the authors have made available.

Even with those caveats, the study adds a compelling entry to the short list of strategies aimed at protecting rather than replacing dopaminergic neurons. It demonstrates that a signaling axis borrowed from neural development can be harnessed in the adult brain through a practical, non-invasive delivery route, and that the resulting protection is measurable both in surviving neurons and in the motor behavior of living animals. If follow-up studies in larger animals confirm the effect and establish a safe dosing profile, intranasal BMP2/6 could eventually join the growing toolkit of biologics delivered nose-to-brain, shifting the therapeutic goal in Parkinson’s disease from managing symptoms to preserving the neurons that produce dopamine in the first place. For a disease in which every preserved neuron counts, that shift would represent a meaningful step forward.

Subject of Research: Intranasal BMP2/6 recombinant protein therapy for neuroprotection of dopaminergic neurons in Parkinson's disease models

Article Title: Intranasal delivery of BMP2/6 recombinant proteins attenuating Parkinsonian pathology-induced neuronal degeneration

Article References: Liu, S., Deng, Y., Si, W., & Wang, Z. (2026). Intranasal delivery of BMP2/6 recombinant proteins attenuating Parkinsonian pathology-induced neuronal degeneration. BMC Medicine. https://doi.org/10.1186/s12916-026-05269-x

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05269-x

Keywords: Parkinson's disease, dopaminergic neurons, BMP2/6, intranasal delivery, neuroprotection, SMAD1 signaling, alpha-synuclein, neural stem cells, 6-hydroxydopamine, preformed fibrils, substantia nigra, recombinant protein therapy

The technology at the heart of the study is the DNA/RNA heteroduplex oligonucleotide, or HDO. Conventional antisense oligonucleotides are single strands of synthetic DNA that bind a target messenger RNA and trigger its destruction. HDOs improve on this design by pairing the active gapmer strand with a complementary RNA or DNA strand, often decorated with a cholesterol molecule. Earlier work had shown that such duplexes silence genes far more potently than their single-stranded parents while producing fewer side effects, apparently because the cholesterol tag helps the construct slip into cells. The researchers designed two versions against alpha-synuclein: alpha-Syn-HDO-1, with a cholesterol-conjugated complementary RNA strand, and alpha-Syn-HDO-2, with a cholesterol-conjugated complementary DNA strand.

The silencing results were striking. A single intrathecal injection—delivered between the vertebrae of the lower spine—reduced alpha-synuclein messenger RNA in the substantia nigra pars compacta, the brain region that loses neurons in Parkinson’s, in a dose-dependent fashion. At the highest dose tested, protein levels fell significantly, and the effect of one injection persisted for at least nine days. The constructs worked equally well against the mouse protein and against human alpha-synuclein in transgenic A53T mice, which carry a mutation that causes aggressive, heritable Parkinson’s disease in people. Scrambled control oligonucleotides had no effect, confirming the sequence specificity of the approach.

How do these bulky duplex molecules actually get inside neurons? Because both constructs carry a cholesterol anchor, the team suspected they might hijack the cell’s cholesterol-import machinery. Blocking LRP1, the low-density lipoprotein receptor–related protein 1, with a specific antibody or with the inhibitor RAP substantially weakened the silencing effect of alpha-Syn-HDO-1 in the substantia nigra, and fluorescent microscopy showed the labeled oligonucleotide co-localizing with LRP1 inside neuroblastoma cells. For alpha-Syn-HDO-2, both LRP1 and the canonical low-density lipoprotein receptor, LDLR, proved necessary for full uptake. The finding suggests that cholesterol conjugation is not merely a delivery gimmick but a deliberate exploitation of endocytic receptors that are naturally abundant on dopaminergic neurons.

With delivery and potency established, the researchers turned to disease models. In the first, an engineered virus forced neurons of the substantia nigra to overproduce human alpha-synuclein, mimicking the gene-multiplication form of familial Parkinson’s. Mice receiving four intrathecal doses of either HDO showed markedly better grip strength and stayed longer on an accelerating rotarod than untreated controls. Under the microscope, tyrosine hydroxylase—the enzyme that marks functional dopaminergic neurons and their striatal terminals—was preserved in treated animals, while western blots confirmed that tyrosine hydroxylase protein, which the viral overexpression had driven down, rebounded toward normal. The treatment had effectively blunted the neurodegenerative cascade at its source.

The second model tested whether the strategy could counter the seeding-and-spreading pathology thought to drive sporadic disease. The researchers injected preformed fibrils, or PFFs—short fragments of synthetic alpha-synuclein fibrils that act as templates, coaxing the cell’s own protein into pathological aggregates—into the substantia nigra. PFFs triggered a characteristic buildup of phosphorylated alpha-synuclein at serine 129, the biochemical signature of Lewy bodies, along with both monomeric and high-molecular-weight oligomeric species. Both HDOs cut these pathological forms back dramatically, restored tyrosine hydroxylase staining in the striatum and substantia nigra, and improved motor performance. Parallel experiments in cultured cells and primary neurons showed the oligonucleotides directly curtailed PFF-induced aggregation, confirming that the benefit flowed from reducing the pool of alpha-synuclein available to misfold.

Perhaps the most consequential discovery concerned what happens downstream of silencing. The brain-derived neurotrophic factor, BDNF, is a survival signal that dopaminergic neurons depend upon, and its levels are known to be reduced in the Parkinsonian brain. Pathological alpha-synuclein, it turns out, suppresses BDNF at multiple points: it drives down the transcription factors—phosphorylated c-Jun, c-Fos, and CREB, and in the fibril model also Nrf2—that bind the promoters of the Bdnf gene, and it directly interferes with TrkB, the receptor through which BDNF signals. Chromatin immunoprecipitation showed that the HDOs reversed the dissociation of these transcription factors from the Bdnf exon I and IV promoters, restoring Bdnf messenger RNA, BDNF protein, and the phosphorylation ratio of TrkB in the substantia nigra.

To prove that this pathway was not merely a bystander, the team deployed a second HDO designed to knock down BDNF itself. When BDNF was silenced, the motor improvements, the preserved tyrosine hydroxylase staining, and the reduced alpha-synuclein pathology conferred by the anti-synuclein constructs all eroded in both disease models, and BDNF protein and TrkB phosphorylation fell in parallel. The logic ran in the other direction as well. Recombinant BDNF protein reduced PFF-induced aggregation in engineered cells, an effect blocked by the TrkB antagonist ANA-12 and mimicked by the TrkB agonist 7,8-dihydroxyflavone. Most persuasively, delivering a virus that overexpressed BDNF directly into the substantia nigra of PFF-treated mice improved grip strength and rotarod performance, restored tyrosine hydroxylase, lowered phosphorylated and oligomeric alpha-synuclein, and raised the p-TrkB/TrkB ratio—all without any direct targeting of the synuclein gene.

This bidirectional evidence sketches a self-reinforcing loop: excess alpha-synuclein starves neurons of BDNF signaling, and diminished BDNF signaling leaves neurons vulnerable to the toxic protein. Breaking the loop at either end—the HDOs from the synuclein side, viral overexpression from the growth-factor side—produced measurable protection. The authors suggest that BDNF could serve not only as a mechanistic node but as a biomarker, allowing clinicians to gauge whether a therapy is actually engaging the pathway that matters. Whether BDNF levels in cerebrospinal fluid or blood track the nigral changes seen here remains to be established.

Important caveats temper the enthusiasm. The receptor-blocking experiments relied on antibodies rather than complete genetic knockdown of LRP1, so the uptake mechanism, while strongly supported, awaits confirmation with tools such as CRISPR or siRNA. The structural differences between the two HDO constructs, and why one engages both LRP1 and LDLR while the other appears to depend mainly on LRP1, are not fully resolved. And the study used only male mice, leaving open the question of whether the benefit extends to females. Translating intrathecal dosing from mice to patients is itself a substantial hurdle, though the same route is already used clinically for other spinal-delivered oligonucleotide drugs. Even so, the convergence of potent silencing, a defined uptake pathway, and a validated downstream survival mechanism makes these cholesterol-tipped duplexes one of the more credible candidates yet for slowing, rather than merely masking, the progression of Parkinson’s disease.

Subject of Research: Gene silencing of alpha-synuclein with heteroduplex oligonucleotides as a therapy for dopaminergic neuron degeneration in Parkinson's disease mouse models

Article Title: Inhibition of Abnormal Elevated α‐Synuclein Ameliorates Dopaminergic Neuron Degeneration in Parkinson's Disease Mouse Model

Article References: Wang, X., Ding, Y., He, L., Kang, X., Geng, X., Sakaue, F., Yokota, T., Zhang, L.-W., Yao, W., & Zhang, J.-C. (2026). Inhibition of Abnormal Elevated α‐Synuclein Ameliorates Dopaminergic Neuron Degeneration in Parkinson's Disease Mouse Model. Aging Cell, 25(10), Article e70717. https://doi.org/10.1111/acel.70717

Image Credits: AI Generated

DOI: 10.1111/acel.70717

Keywords: Parkinson's disease, alpha-synuclein, heteroduplex oligonucleotides, gene silencing, BDNF, TrkB signaling, dopaminergic neurons, substantia nigra, preformed fibrils, LRP1, neurodegeneration, antisense therapy

The research, led by James M. Hennegan and colleagues at the University of Southampton, focused on Fc gamma receptor IIb, the only inhibitory member of the Fc gamma receptor family that is conserved across species. These receptors normally serve as molecular sentinels of the immune system, binding the Fc domain of IgG antibodies and calibrating immune cell responses through a balance of activating and inhibitory signals. FcγRIIb restrains immune activation via its immunoreceptor tyrosine-based inhibitory motif, or ITIM, which recruits intracellular phosphatases when engaged. Crucially, the receptor is not confined to the periphery. Previous work has documented its expression on both neuronal and microglial membranes within the central nervous system, particularly under conditions of proteopathic stress, and earlier in vitro studies had shown that fibrillar alpha-synuclein binds directly to FcγRIIb, triggering downstream SHP-1/2-c-Src signalling that facilitates the protein’s internalisation.

What remained unresolved was whether this receptor genuinely governs alpha-synuclein spread in a living brain, rather than merely in a culture dish. To answer this question, the team turned to the preformed fibril, or PFF, model of synucleinopathy, in which synthetic fibrils of recombinant human alpha-synuclein are injected into the dorsal striatum of mice. The fibrils, fragmented by sonication into particles smaller than 50 nanometres and validated by transmission electron microscopy and Thioflavin-T fluorimetry, seed the aggregation of the brain’s own alpha-synuclein, generating Lewy body-like pathology that spreads along anatomically connected circuits in a manner that closely mirrors the human disease. The researchers compared wild-type C57BL/6 mice with mice in which the Fcgr2b gene had been deleted, and confirmed at both the RNA and protein levels that the knockout abolished receptor expression in the brain and spleen without altering other Fc gamma receptor family members or the mice’s own production of alpha-synuclein.

The results were striking. In primary cortical neurons cultured from embryonic tissue, exposure to preformed fibrils produced abundant phosphorylated alpha-synuclein, the pathological modification found at serine 129 that defines Lewy bodies, in wild-type cultures. Neurons lacking FcγRII showed an 88 percent reduction in this pathological staining, with far fewer inclusions in both the cell bodies and the neuritic arbours. When the team moved into living animals, injecting fibrils unilaterally into the striatum, the difference was even more dramatic. Thirty days after injection, wild-type mice had already developed robust phosphorylated alpha-synuclein pathology in the ipsilateral substantia nigra pars compacta, whereas knockout mice showed a near-complete absence of staining. By ninety days, wild-type brains were riddled with inclusions across the prefrontal cortex, primary motor cortex, entorhinal cortex, amygdala and substantia nigra, with muted deposition appearing even in the contralateral hemisphere, consistent with trans-hemispheric propagation.

The knockout mice were largely spared this anatomical cascade. Quantitative image analysis revealed reductions in pathological burden ranging from more than 70 percent in the ipsilateral substantia nigra to nearly 99 percent in the prefrontal and motor cortices, indicating that the receptor is not merely permissive but fundamental for efficient seeding and trans-neuronal propagation of the pathology along synaptically connected pathways. Distribution maps generated from the immunohistochemical data visualised the stark divergence between the two genotypes, with the wild-type hemisphere dotted with pathological signal and the knockout hemisphere almost clean. Control injections of monomeric, non-fibrillar alpha-synuclein produced no pathology in either genotype, confirming the specificity of the fibril-seeding response.

The protective effect extended beyond protein aggregation to the neurons themselves. Neuroinflammation is a central component of Parkinson’s pathogenesis, and in wild-type mice the fibril injection provoked a pronounced rise in microglial density, marked by increased Iba1 staining, and elevated expression of FcγRI, the high-affinity IgG receptor that appears on activated microglia. In knockout mice, this response was substantially blunted, with roughly a 72 percent reduction in Iba1-positive microglial density and a 29 percent decrease in FcγRI expression in the injected striatum at ninety days. The authors interpret this dampened gliosis as a secondary consequence of the reduced alpha-synuclein burden, suggesting that the receptor’s primary contribution to disease may be neuron-intrinsic, with impaired fibril internalisation limiting the downstream activation of glial cells.

Most importantly from a therapeutic standpoint, the loss of FcγRII preserved the nigrostriatal dopaminergic system. Wild-type mice injected with fibrils showed a marked reduction in tyrosine hydroxylase-positive fibre density in the dorsal striatum and a significant loss of dopamine neuron cell bodies in the substantia nigra by ninety days, the classic signature of progressive neurodegeneration in this model. Knockout mice maintained fibre density and neuronal counts equivalent to monomer-injected controls at both time points. Behavioural testing, conducted monthly before the animals were killed, suggested functional correlates of this protection: wild-type fibril-injected mice displayed reduced locomotor activity and exploratory drive in the open field and increased descent latency in the pole test, while knockout mice performed normally across all paradigms. The authors caution that the small cohort sizes render these behavioural findings suggestive rather than definitive, but their directionality aligns with the histological preservation.

To translate these genetic findings into a pharmacological strategy, the team exploited transgenic mice expressing human FcγRIIb and tested two monoclonal antibodies, BI-1206 and BI-1607, that selectively antagonise the human receptor. One antibody carried a wild-type Fc domain, while the other incorporated an N297Q substitution rendering it Fc-null, allowing the researchers to distinguish effects of receptor blockade itself from those mediated by Fc-driven engagement of activating Fc gamma receptors on immune cells. The antibodies were co-injected intracranially with the fibrils and supplemented with systemic dosing at 10 milligrams per kilogram to maintain circulating levels. Thirty days later, both antibody formats had produced a roughly 90 percent decrease in phosphorylated alpha-synuclein burden in the striatum and substantia nigra relative to an isotype control, with comparable efficacy between the Fc-wild-type and Fc-null variants. This equivalence suggests that blockade works predominantly through steric interference with the fibril-binding interface on the receptor, preventing alpha-synuclein uptake and pathological templating at the injection site before spread can begin.

The implications reach well beyond the laboratory. The antibodies used in this study are already advancing through oncology clinical trials, where FcγRIIb-directed therapeutics are being evaluated in CD32b-positive B-cell lymphomas, establishing a safety, tolerability and pharmacodynamic footprint that could accelerate repurposing toward neurodegenerative indications. Because the strategy targets the cellular entry route for fibrils rather than the protein aggregates themselves, it offers a mechanistically distinct complement to conventional anti-alpha-synuclein immunotherapies, which have struggled in clinical trials. Other receptors implicated in alpha-synuclein uptake, including LAG3, APLP1, the alpha-3 subunit of the sodium-potassium ATPase and connexin 32, suggest that fibrils may engage multiple overlapping entry pathways, but the magnitude of protection seen here indicates FcγRIIb is an especially influential conduit.

The authors are careful to note the limitations of the work. The initial knockout experiments used only male animals, cohort sizes were small, and tyrosine hydroxylase staining alone cannot distinguish frank neuronal loss from reduced expression or dysfunction without an independent pan-neuronal counterstain. The prophylactic antibody paradigm also does not address therapeutic intervention once pathology is established, and intracerebral delivery does not recapitulate the pharmacokinetics of systemic administration. Nevertheless, the convergence of genetic deletion and antibody blockade on the same outcome, a profound impairment of alpha-synuclein seeding, propagation and neurotoxicity in vivo, marks FcγRIIb as a pivotal and druggable regulator of synucleinopathy, and raises the tangible prospect that a receptor once studied for its role in immune regulation and cancer immunotherapy may become a target for slowing the progression of Parkinson’s disease.

Subject of Research: The role of the FcγRIIb receptor in alpha-synuclein propagation and its blockade as a therapeutic strategy for Parkinson's disease

Article Title: Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo

Article References: Hennegan, J. M., Hurley, M. J., Colley, M., Cox, K. L., Douglas, L. R., Duriez, P. J., Oldham, R. J., Cragg, M. S., Frendéus, B., Roghanian, A., & Teeling, J. L. (2026). Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo. Acta Neuropathologica, 152(1), Article 40. https://doi.org/10.1007/s00401-026-03082-7

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03082-7

Keywords: Parkinson's disease, alpha-synuclein, FcγRIIb, CD32b, preformed fibrils, neurodegeneration, monoclonal antibodies, microglia, substantia nigra, prion-like propagation, immunotherapy, synucleinopathy